Our Mission: Improving and Extending the Lives of Patients with Cancer
 
 
 

News & Events

2008 News Archive
 

12/09/2008
Celator® Pharmaceuticals presents Phase 1 results with CPX-351 in patients with advanced leukemia at the American Society of Hematology meeting

11/25/2008
Celator® Pharmaceuticals to present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference

11/18/2008
Celator® Pharmaceuticals announces enrollment of first patient in Phase II study with CPX-351

10/23/2008
Celator® Pharmaceuticals to present at 2008 BIO Investor Forum

9/4/2008
Celator® Pharmaceuticals receives orphan drug designation for anticancer agent CPX-351

7/29/2008
Celator® Pharmaceuticals raises series C financing in excess of $22.5 million

6/16/2008
Celator® Pharmaceuticals to Present at 2008 BIO International Convention

6/3/2008
Celator® Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer

5/9/2008
Celator® Pharmaceuticals Announces Appointment of Scott Jackson as CEO

4/16/2008
Celator® Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations

2/5/2008
Celator® Pharmaceuticals to present at 10th Annual BIO CEO and Investor Conference

1/14/2008
Joseph A. Mollica Named Chairman of Celator® Pharmaceuticals Board of Directors

 

 

News Links:
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Upcoming Events

 

 

 

 

 

 

 

 

 

 

 

 
© 2009 Celator Pharmaceuticals, Inc. All rights reserved. Celator®, Celator Pharmaceuticals®, the Celator logo and CombiPlex® are registered trademarks of Celator Pharmaceuticals, Inc. Contact webmaster.